City of Pharr continues commitment to UTRGV School of Medicine with $500,000 donation

Breaking NewsCommunity NewsEducation
531

Translate to Spanish or other 102 languages!

Pictured, from left to right, are Dr. Steven Lieberman, interim dean of the UTRGV School of Medicine; Dr. John H. Krouse, incoming dean of the UTRGV School of Medicine; UTRGV President Guy Bailey; City of Pharr Mayor Dr. Ambrosio Hernandez, and City of Pharr Commissioners Eleazar Guajardo, Ricardo Medina, Ramiro Caballero and Daniel Chavez. UTRGV Photo by Paul Chouy.

Mega Doctor News

- Advertisement -

PHARR, TEXAS — JUNE 13, 2017 — The City of Pharr continued its support of The University of Texas Rio Grande Valley School of Medicine (SOM) by presenting the school with a check for $500,000 Tuesday, June 13. This is the second donation the City of Pharr has made to SOM as part of a memorandum of understanding UTRGV signed with Pharr and other local government entities. The City of Pharr has committed to give $500,000 annually to support the School of Medicine.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
New Pediatric Fast Track Emergency Room Unit Started Construction in Harlingen
Next article
ALERT: RGV Healthcare Provider Patient Records Vulnerable to Hacker Attacks

More Articles

Scientists Reverse Brain Aging With a Nasal Spray

Picture this: your brain is a high-performance engine. Over decades, it doesn’t just wear down; it also starts to run hot.

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 
- Advertisement -